Luminex’s xMAP Technology is built on proven, existing technology — flow cytometry, microspheres, lasers, digital signal processing and traditional chemistry — that have been combined in a unique way. Featuring a flexible, open-architecture design, xMAP Technology can be configured to perform a wide variety of bioassays quickly, cost-effectively and accurately.
First, Luminex color-codes tiny beads, called microspheres, into 100 distinct sets. Each bead set can be coated with a reagent specific to a particular bioassay, allowing the capture and detection of specific analytes from a sample. Within the Luminex compact analyzer, lasers excite the internal dyes that identify each microsphere particle, and also any reporter dye captured during the assay. Many readings are made on each bead set, further validating the results. In this way, xMAP Technology allows multiplexing of up to 100 unique assays within a single sample, both rapidly and precisely.
Shortened time-to-results by favorable reaction kinetics of liquid bead array approach, with smaller sample requirements
Liquid reaction kinetics give faster, more reproducible results than with solid, planar arrays
Focused, flexible multiplexing in the range of 1 to 100 analytes meets the needs of a wide variety of applications - protein expression profiling, focused gene expression profiling, autoimmune disease, genetic disease, molecular infectious disease, and HLA testing
Open architecture platform allows market leading companies to provide compatible kits and software
xMAP Technology is experiencing rapid adoption across many segments of the life sciences. See the growing bibliography list of publications in the key areas of Protein Expression Profiling, Molecular and Immunodiagnostics, HLA testing, and Biodefense/Environmental.
Open-architecture xMAP® Technology, developed by Luminex, is ideally suited to a wide range of applications throughout the drug-discovery and diagnostics fields, as well as basic research.
